2012 Press Coverage

To receive regular updates, including all of Clinuvel's announcements, you can subscribe to our email database here.

DateTitleLink
03/01/2012

Clinuvel has done its reimbursement homework for orphan drug Scenesse but can it make money

Link
17/01/2012

Clinuvel Trading At Nine Month Highs

Link
30/01/2012

EPP

Link
06/02/2012

Clinuvel files treatment for rare skin disease with EMA

Link
05/04/2012

Clinuvel set to accelerate phase III study of Scenesse

Link
21/04/2012

Classmates Rally Around Vernon Students

Link
23/05/2012

Clinuvel starts final trial of Scenesse in EPP

Link

Investors' Blog Posts

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Read More

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Read More

Related Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Investor Spotlight